CUL4B Promotes Temozolomide Resistance in Gliomas by Epigenetically Repressing CDNK1A Transcription

CUL4B Promotes Temozolomide Resistance in Gliomas by Epigenetically Repressing CDNK1A Transcription

Resistance to temozolomide (TMZ), the first-line chemotherapeutic drug for glioblastoma (GBM) and anaplastic gliomas, is one of the most significant obstacles in clinical treatment. TMZ resistance is regulated by complex genetic and epigenetic networks. Understanding the mechanisms of TMZ resistance...

Full description

Bibliographic Details
Main Authors: Xiang Ye, Xiaochen Liu, Min Gao, Li Gong, Fei Tian, Yangli Shen, Huili Hu, Gongping Sun, Yongxin Zou, Yaoqin Gong
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-04-01
Series:Frontiers in Oncology
Subjects:
CUL4B
p21
temozolomide resistance
glioma
epigenetic regulation
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.638802/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.638802/full

Similar Items